On February 28, 2017, the Patent Trial and Appeal Board ruled in favor of Finnegan client Pozen Inc., deciding that Lupin Ltd. had not shown that the challenged claims in two patents covering Vimovo (Pozen's arthritis and ulcer drug) were invalid.
The lawsuit came after Lupin sought regulatory approval to market a generic version of Vimovo. Lupin sought the cancellation of every claim in the two patents. They argued that the active ingredients in Vimovo were well-known. The PTAB found that Lupin "failed to show by a preponderance of the evidence that the skilled artisan would have had a reasonable expectation of success in achieving the claimed invention."
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.